

VALBIOTIS: Pascal SIRVENT appointed Director of Discovery and Preclinical Research

La Rochelle, September 14th, 2017 (7:30 CEST) - VALBIOTIS (FR0013254851 - ALVAL / PEA/SME eligible), a company that specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients, today announced the arrival of Pascal SIRVENT as Director of Discovery and Preclinical Research from September 1st, 2017.

“Pascal SIRVENT has been contributing to our company’s growth for several years as a member of the Scientific Committee and head of collaborative projects between the University of Clermont Auvergne and VALBIOTIS. Today we are delighted to welcome him within the company as Director of Discovery and Preclinical Research. Co-inventor of several technologies crucial to the development of VALBIOTIS, Pascal has extensive preclinical research expertise. He has published some 30 articles in international scientific journals and given numerous presentations at congresses. His presence in our VALBIOTIS research division is a tremendous asset for our development. It will ensure the unbroken continuity of our research and strengthen our expertise in discussions with the agro-food and pharmaceutical industry”, said Sébastien PELTIER, CEO of VALBIOTIS.

“VALBIOTIS holds great promise in the world of biotechnology and unique cardiometabolic disease prevention potential, both in terms of prevention and nutritional support. I’m delighted that I will now be more involved in the team as Director of Discovery and Preclinical Research, and I’m looking forward to playing a more active role in future developments”, said Pascal SIRVENT.



With over 10 years experience in research, Pascal SIRVENT will be bringing his in-depth expertise in metabolic diseases and nutrition.

Pascal SIRVENT has been a lecturer at the University of Clermont Auvergne since 2008, and has headed the establishment’s technical functional assessment platform since 2010. He has also set up several international scientific partnerships with Vanderbilt University (Nashville, USA), the Maine Medical Center Research Institute (Portland, Oregon) and the University of Texas (Houston, USA) as part of research projects on the pathophysiology of type 2 diabetes. The arrival of Pascal SIRVENT will notably make it easier for VALBIOTIS to work with one of the largest diabetes research centers in the US. In 2005, Pascal SIRVENT obtained a PhD in Biological and Biochemical Health Sciences from the Montpellier I University and habilitation to conduct research in 2016.

ABOUT VALBIOTIS

VALBIOTIS specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. Its products are made for manufacturers in the agro-food and pharmaceutical industries. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.

Valbiotis was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand, where the company opened a second office. These partnerships have enabled Valbiotis to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. Valbiotis is a member of the “BPI Excellence” network and received the “Innovative Company” status accorded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF).

Find out more about VALBIOTIS:

<http://valbiotis.com/>



CONTACTS

FINANCIAL COMMUNICATION

ACTIFIN

Stéphane RUIZ
+33 1 56 88 11 14
sruiz@actifin.fr

PRESS RELATIONS

ALIZE PR

Caroline Carmagnol / Wendy Rigal
+33 1 44 54 36 66
valbiotis@alizerp.com



Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL

